Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply.
Vitamin D3 potentiates myelination and recovery after facial nerve injury.
Activities of the European multiple sclerosis platform.
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Transplanted microvascular endothelial cells promote oligodendrocyte precursor cell survival in ischemic demyelinating lesions.
Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica.
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis.
Adaptive Immune Responses in CNS Autoimmune Disease: Mechanisms and Therapeutic Opportunities.
Multimodal imaging of subventricular zone neural stem/progenitor cells in the cuprizone mouse model reveals increased neurogenic potential for the olfactory bulb pathway, but no contribution to remyelination of the corpus callosum.
Quantifying the local tissue volume and composition in individual brains with magnetic resonance imaging.
Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial.
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis.
Neurological disorders: Differential methylation in multiple sclerosis.
Integrated transcriptomic-proteomic analysis using a proteogenomic workflow refines rat genome annotation.
MRI in the Evaluation of Acute Visual Syndromes.
Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.
Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of Multiple Sclerosis.
Risk Factors for Suicidal Ideation in Patients Feeling Severely Affected by Multiple Sclerosis.
Cognitive motor interference during walking in multiple sclerosis using an alternate letter alphabet task.
Safety and efficacy of natalizumab in children with multiple sclerosis.
Ipsilateral uveitis and optic neuritis in multiple sclerosis.
A case of multiple sclerosis and celiac disease.
Natalizumab therapy for multiple sclerosis.
Multiple sclerosis affects skeletal muscle characteristics.
Pages
« first
‹ previous
…
456
457
458
459
460
461
462
463
464
…
next ›
last »